Home
You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.
Latest Professional Issues Articles
Popular Professional Issues Articles
Highly Recommended Professional Issues Articles
Email to a Friend
Send a link to this page to your friends and colleagues.
Common Glucose-Control Drug May Delay or Even Prevent Onset of Type 2
Interestingly, the study was originally intended to last three years. But the results from the administration of volglibose came so quickly and dramatically after less than a year that the study was terminated.
Voglibose*, a generic drug often used in combination with sulfonylureas to control blood glucose levels, appears to delay or even prevent the onset of diabetes in people who are predisposed to the disease.
A study conducted by the Jutendo University School of medicine in Tokyo concluded that patients from impaired glucose tolerance were 40 percent less likely to develop type 2 diabetes if they regularly took volglibose three times daily.
The study tracked 1,780 Japanese patients who were considered to be at high risk of developing type 2. A little more than half the patients-897-took volglibose three times a day while the remaining 883 patients took a placebo.
While 106 of the placebo recipients went on to develop full-blown type 2, only 50 of the patients taking voglibose did so. Voglibose recipients were also 54 percent more likely than their placebo-taking counterparts to achieve normal blood sugar levels.
Interestingly, the study was originally intended to last three years. But the results from the administration of volglibose came so quickly and dramatically after less than a year that the study was terminated.
Results of the study were recently published in the British medical journal The Lancet.
*Voglibose is defined as an alpha-glucosidase inhibitor that is used to lower post-meal blood sugar levels in people with type 2 diabetes.
Categories: Blood Glucose, Blood Sugar, Diabetes, Diabetes, Medications Research, Professional Issues, Type 2 Issues, Voglibose
You May Also Be Interested In...
-
Diabetes Health
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.
-
Topics
- Diabetic / Diabetes Health
- Type 1 / 1.5 Diabetes
- Type 2 Diabetes
- Blood Glucose / Sugar
- High/Low Blood Sugar / Fast Acting Glucose
- Insulin- Pumps, Pens & Syringes
- Continuous Glucose Monitors, CGM, Infusion Sets
- Type 2 Medications
- Hyperglycemia
- Hypoglycemia
Comments
Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.
When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.
For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.
Don't have your Diabetes Health Username? Register now and add your comments to all our content.
Register...
Register your Diabetes Health Username here.
Have Your Say...